- Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
- Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences in June 2024
- Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
- Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
- Cue Biopharma to Host Business Update Call and Webcast
- Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
- Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.08 |
---|---|
High | 1.09 |
Low | 0.972 |
Bid | 0.98 |
Offer | 1.03 |
Previous close | 1.08 |
Average volume | 818.05k |
---|---|
Shares outstanding | 48.64m |
Free float | 48.31m |
P/E (TTM) | -- |
Market cap | 47.67m USD |
EPS (TTM) | -1.07 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼